PMID- 33583740
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1437-7780 (Electronic)
IS  - 1341-321X (Linking)
VI  - 27
IP  - 6
DP  - 2021 Jun
TI  - Comparison between the prophylactic effects of amoxicillin 24 and 48 hours 
      pre-operatively on surgical site infections in Japanese patients with impacted 
      mandibular third molars: A prospective cohort study.
PG  - 845-851
LID - S1341-321X(21)00030-1 [pii]
LID - 10.1016/j.jiac.2021.01.018 [doi]
AB  - INTRODUCTION: According to the guidelines, the dosage for mandibular wisdom tooth 
      extraction (MWTE) varies within the administration period. There is a 24-fold 
      difference between the minimum and maximum doses. If an appropriate antimicrobial 
      can be administered without increasing incidence of surgical site infection 
      (SSI), it may lead to a global action plan on antimicrobial resistance (AMR). 
      Therefore, we prospectively surveyed incidence of SSI post-operatively and use of 
      oral antibiotics (OA) for MWTE. METHODS: Subjects were patients who underwent 
      MWTE in our dental outpatient clinic from May 2019 to April 2020. Two groups were 
      formed depending on type of administration period they received: 24 h and 48 h 
      after surgery. The following information was collected: (1) patient factors (age, 
      gender, body mass index, presence/absence of preoperative medication, diagnosis, 
      impacted wisdom tooth status; (2) surgical factors (operative time, 
      presence/absence of closure, presence/absence of hemostat, doctor career, type 
      and frequency of painkiller); (3) relationship between administration period of 
      OA and SSI occurrence; and (4) details of SSI. RESULTS: Three hundred forty 
      subjects were analyzed, all of which used amoxicillin. There were 106 cases in 
      24 h group and 234 cases in 48 h group. The total incidence of SSI was 1.1% 
      (4/340 cases), with 0.9% (1/106 cases) in 24 h group and 1.3% (3/234 cases) in 
      48 h group; there was no difference between the two groups. CONCLUSION: Our study 
      suggests that amoxicillin (250 mg/dose every 8 h x 3 doses beginning 1 h before 
      surgery) might be sufficient in preventing SSI in Japanese dental patients 
      without SSI risk factors.
CI  - Copyright (c) 2021 Japanese Society of Chemotherapy and The Japanese Association 
      for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
FAU - Yoshida, Kensuke
AU  - Yoshida K
AD  - Division of Oral and Maxillofacial Surgery, Faculty of Dentistry & Graduate 
      School of Medical and Dental Sciences, Niigata University, Japan; Division of 
      Hospital Pharmacy, Niigata University Medical and Dental Hospital, 1-754, 
      Asahimachi-dori, Chuo-ku, Niigata (city), 951-8520, Japan. Electronic address: 
      kensukeyoshida-nii@umin.ac.jp.
FAU - Kodama, Yasumitsu
AU  - Kodama Y
AD  - Division of Oral and Maxillofacial Surgery, Faculty of Dentistry & Graduate 
      School of Medical and Dental Sciences, Niigata University, Japan.
FAU - Nishikawa, Atsushi
AU  - Nishikawa A
AD  - Division of Oral and Maxillofacial Surgery, Faculty of Dentistry & Graduate 
      School of Medical and Dental Sciences, Niigata University, Japan.
FAU - Estacio Salazar, Andrea Rei
AU  - Estacio Salazar AR
AD  - Division of Oral and Maxillofacial Surgery, Faculty of Dentistry & Graduate 
      School of Medical and Dental Sciences, Niigata University, Japan.
FAU - Toyama, Akira
AU  - Toyama A
AD  - Division of Hospital Pharmacy, Niigata University Medical and Dental Hospital, 
      1-754, Asahimachi-dori, Chuo-ku, Niigata (city), 951-8520, Japan.
FAU - Takagi, Ritsuo
AU  - Takagi R
AD  - Division of Oral and Maxillofacial Surgery, Faculty of Dentistry & Graduate 
      School of Medical and Dental Sciences, Niigata University, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210211
PL  - Netherlands
TA  - J Infect Chemother
JT  - Journal of infection and chemotherapy : official journal of the Japan Society of 
      Chemotherapy
JID - 9608375
RN  - 0 (Anti-Bacterial Agents)
RN  - 804826J2HU (Amoxicillin)
SB  - IM
MH  - Amoxicillin/therapeutic use
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Antibiotic Prophylaxis
MH  - Humans
MH  - Japan/epidemiology
MH  - *Molar, Third/surgery
MH  - Prospective Studies
MH  - *Surgical Wound Infection/epidemiology/prevention & control
OTO - NOTNLM
OT  - Dental outpatient clinic
OT  - Mandibular third molar surgery
OT  - Oral antimicrobial prophylaxis
OT  - Prospective cohort study
OT  - Surgical site infection (SSI)
COIS- Declaration of competing interest None All authors declare no competing 
      interests.
EDAT- 2021/02/16 06:00
MHDA- 2021/06/25 06:00
CRDT- 2021/02/15 05:40
PHST- 2020/09/20 00:00 [received]
PHST- 2021/01/25 00:00 [revised]
PHST- 2021/01/28 00:00 [accepted]
PHST- 2021/02/16 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2021/02/15 05:40 [entrez]
AID - S1341-321X(21)00030-1 [pii]
AID - 10.1016/j.jiac.2021.01.018 [doi]
PST - ppublish
SO  - J Infect Chemother. 2021 Jun;27(6):845-851. doi: 10.1016/j.jiac.2021.01.018. Epub 
      2021 Feb 11.